Myriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a...


Myriad Genetics (MYGN -2.9%) shares slide after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes. Goldman Sachs cuts shares to Neutral from Buy on concerns that a final decision likely won't be reached before midyear. But Jefferies maintains its Buy rating, believing MYGN's patents should ultimately be upheld.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs